金陵藥業 (000919.SZ)

7.22 +0.26 (+3.74%) 收市：03:04PM CST

金陵藥業

Jinling Pharmaceutical Building
No. 238, Zhongyang Road
Nanjing 210009
China
86 25 8311 8511
https://jlyy1999.com

版塊: Healthcare
行業: Drug Manufacturers - Specialty & Generic
全職員工: 4,880

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Yang Wang	VP, Chief Accountant & Non-Independent Director	無	無	1979
Mr. Sheng Chen	VP & Non-Independent Director	無	無	1970
Mr. Jian Wang	VP & Non-Independent Director	無	無	1973
Mr. Yajun Chen	President	無	無	1969
Mr. Jun Yang Xu	Secretary	無	無	1962
Mr. Xinning Zhu	Assistant to President	無	無	1971
Mr. Wei Guo Tang	Executive Vice President	無	無	1963
Mr. Hai Chen	President, Board Secretary & Non-Independent Director	無	無	1980
Zhenxin Xi	General Manager Assistant	無	無	無

截止 為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 CNY。

描述

Jinling Pharmaceutical Company Limited manufactures and sells pharmaceutical products and medical devices in China. The company provides Mailuoning injection/oral solutions for the treatment of thromboangiitis obliterans, arteriosclerosis obliterans, cerebral thrombosis and sequelae, polyarteritis, acute arterial embolism of extremities, diabetic gangrene, intravenous thrombus, thrombophlebitis, etc.; ferrous succinate tablets for the prevention and treatment of iron deficiency anemia; lentinan injection for the treatment of malignant tumors; and absorbable gelatin sponges for the treatment of wound hemostasis. It also offers medical and health care services. Jinling Pharmaceutical Company Limited was founded in 1998 and is headquartered in Nanjing, China.

公司管治

截至 無 止，金陵藥業 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。